期刊文献+

子宫内膜间质肉瘤预后及复发转移相关因素分析 被引量:8

下载PDF
导出
摘要 目的分析子宫内膜间质肉瘤(ESS)的预后及复发转移相关因素。方法回顾性37例ESS患者的临床资料。结果本组患者2、5a累积生存率分别为73%和59%。低度恶性ESS(LGESS)、Ⅲ-Ⅳ期患者累积生存率与高度恶性ESS(HGESS)、Ⅰ-Ⅱ期患者相比,P均〈0.05;术后接受放、化疗者与未接受放、化疗者相比,P均〉0.05。本组共有23例(62%)患者出现复发转移,中位复发转移时间为25个月。LGESS患者、保留卵巢功能者、接受放疗者与HGESS患者、未保留卵巢功能者、未接受放疗者复发转移率相比P〈0.05;术后接受化疗与未接受化疗者相比P〉0.05。结论ESS的预后与其恶性程度和临床分期相关;复发转移与恶性程度、是否保留卵巢功能及是否接受放疗有关。
作者 马骏
机构地区 沂源县人民医院
出处 《山东医药》 CAS 北大核心 2010年第6期44-45,共2页 Shandong Medical Journal
  • 相关文献

参考文献8

二级参考文献45

  • 1周应芳,吴北生,李辉,郑淑蓉.CA_(125)测定对子宫肌腺病的诊断价值[J].中华妇产科杂志,1996,31(10):590-593. 被引量:72
  • 2连利娟.卵巢癌单克隆抗体在诊断上的应用[J].中华妇产科杂志,1985,20(5):257-257.
  • 3袁耀萼.临床妇科病理学[M].北京:人民卫生出版社,1998.350.
  • 4Chu PG, Arber DA,Weiss LM,et al. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors:an immunohistochemical comparison of 34 cases[J]. Mod Pathol, 2001,14(5) :465 - 471.
  • 5Koss LG, Spiro RH, Brunschwig A.Endometrial stromal sarcoma[J] .Surg Gynecol Obstet, 1965,121: 531 - 537.
  • 6Scully RE, Bonfiglio TA, Kurman RJ. WHO histological typing of female genital tract tumours[ M]. Springer: Verlag, 1994.18- 19.
  • 7Agoff SN, Grieco VS, Garcia R, et al. Immunohistochemical distinction of endometrial stromal sarcoma and cellular leiomyoma[J]. Appl Immunohistochem Molecul Morphol,2001,9(2): 164 - 169.
  • 8Clement PB. Pathology of the uterine corpus[J]. Hum P athol, 1991,22(8) :776 - 791.
  • 9Milojkovic M, Hrgovic Z, Hrgovic I, et al. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis. Arch Gynecol Obstet,2004 ,269 :176-180.
  • 10Bilgin T, Karabay A, Dolar E, et al. Peritoneal tuberculosis with pelvic abdominal mass, ascites and elevated CA 125 mimicking advanced ovarian carcinoma: a series of 10 cases.Int J Gynecol Cancer,2001,11:290-294.

共引文献95

同被引文献70

  • 1刘静,刘惠民,魏焕萍.子宫肉瘤26例临床病理分析[J].武警医学院学报,2006,15(1):49-51. 被引量:2
  • 2王强修,卢宝彦,陈立华,林晓燕,程显魁,王家耀.子宫内膜间质肉瘤的临床病理和免疫组织化学分析[J].中华肿瘤防治杂志,2007,14(6):454-456. 被引量:6
  • 3Tavassoli FA, Devilee P. WHO classification of tumours, pathology and genetics of tumours of the breast and female genital organs[M]. Lyon:LARC Press,2003. 233-236.
  • 4Patsner B, Mann WJ. Use of serum CA125 in moruitoring patients with uterine sarcoma [J]. Cancer, 1988, 62(7): 1355-1358.
  • 5潘凌亚.子宫肉瘤的临床表现及治疗[M]//连利娟.林巧稚妇科肿瘤学.第4版.北京:人民卫生出版社,2006:487-504.
  • 6Berehuek A, Rubin SC, Hoskins WJ, et al. Treatment of endo- metrial stromal tumors[J]. Gynecol Oneol, 1990,36 (1) .. 60-65.
  • 7Chen SS. Propensity of retroperitoneal lymph node metastasis in patients with stage. I sarcoma of the uterus[J]. Gynecol Oncol, 1989,32(2) .. 215:217.
  • 8Shoji K, Oda K, Nakagawa S, et al. Aromatase inhibitor anas- trozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case repor[J]. Med Oncol, 2011,28(3) : 771-774.
  • 9Peter W Callen.妇产科超声学[M].北京:人民卫生出版社,2010:905-906.
  • 10Jibiki M, Inoue Y, Sugano N, et al. Tumor thrombecto- my without bypass for low-grade malignant tumors exten- ding into the inferior vena cava: report of two cases [ J ]. Surg Today, 2006,36 ( 5 ) :465 -469.

引证文献8

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部